
IPO Milestone Pharmaceuticals
Фаза 3 биотехнологической терапии для лечения сердечного ритма.
Индустрия: Health Care
Тикер: NASDAQ : MIST
Параметры IPO
Дата IPO | 08.05.2019 |
Дата начала торгов | 09.05.2019 |
Цена размещения | $15 |
Ценовой диапазон | $14 - $16 |
Акций к размещению | 5.5 млн. |
Общее кол-во акций | 25.67 млн. |
Объем размещения | $82.5 млн. |
Капитализация на IPO | $385 млн. |
EV на момент IPO | $225 млн. |
Андеррайтер | Jefferies |
Проспект эмиссии |
Доходность (26.01.2021) | 8 -46.7% |
GAP (+1D) | 15.61 +4.1% |
Доходность (+1D) | 15.37 +2.5% |
Доходность (+3M) | 16 +6.7% |
Доходность (+6M) | 19.75 +31.7% |
Отчетный день | 14.05.2020 |
Lock-Up (3M) | 12.08.2019 |
Lock-Up (6M) | 05.11.2019 |
Окончание тихого периода | 03.06.2019 |
Информация о компании
Штаб-квартира | Montreal, Canada |
Год основания | 2003 |
Количество сотрудников | 23 |
Website | Milestone Pharmaceuticals |
We are a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker that we designed and are developing as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT, as they occur. PSVT is a rapid heart rate condition that starts and stops without warning, often experienced by patients with symptoms including palpitations, sweating, chest pressure or pain, shortness of breath, sudden onset of fatigue, lightheadedness or dizziness, fainting and anxiety. Calcium channel blockers have long been approved for the treatment of PSVT as well as other cardiac conditions. For episodes of PSVT, however, calcium channel blockers are administered intravenously under medical supervision, usually in the emergency department. Etripamil's combination of convenient delivery, rapid-onset and short duration of action has the potential to shift the current treatment paradigm away from the burdensome and costly emergency department setting. If approved, we believe that etripamil will be the first self-administered therapy for the rapid termination of episodes of PSVT wherever and whenever they occur.
Рост выручки
̶Прибыльность
̶Долги
LowДиапазон размещения
В диапазонеСентимент на рынке IPO
PositiveОбъем размещения
SmallФинансовые показатели
Продажи за год ($M) | - |
Рост г/г | - |
Валовая маржа | - |
EBITDA | - |
Чистая прибыль($M) | -23 |
Оценочные показатели
Рыночная капитализация ($M) | 385 |
Стоимость предприятия ($M) | 225 |
EV/Sales | - |
EV/EBITDA | - |
P/E | - |
Отчет о прибылях и убытках
FY Dec ($M) | 2017 | 2018 | Рост г/г |
---|---|---|---|
Продажи ($M) | - | - | 0% |
Валовая прибыль ($M) | - | - | 0% |
EBITDA ($M) | -8 | -23 | - |
EBIT ($M) | -8 | -23 | - |
Баланс
31/12/18 ($M) | До IPO | После IPO | Изменение |
---|---|---|---|
Денежные средства ($M) | 86 | 160 | 86% |
Активы ($M) | 88 | 162 | 84% |
Долги ($M) | - | - | - |
Капитал ($M) | 84 | 158 | 88% |
Последние 10 размещений в секторе Health Care
Компания | Тикер | Рейтинг | Дата | Цена | Изменение |
---|---|---|---|---|---|
INNV | Bullish | 03.03.2021 | $21 | +14.7% | |
TLIS | Bullish | 11.02.2021 | $16 | -8.4% | |
NEXI | Bullish | 11.02.2021 | $17 | +9.9% | |
DBTX | Bullish | 11.02.2021 | $18 | -18.4% | |
BVS | Bullish | 10.02.2021 | $13 | -11.6% | |
SGFY | Bullish | 10.02.2021 | $24 | +18% | |
APR | Bullish | 10.02.2021 | $20 | +7.9% | |
ADAG | Bullish | 08.02.2021 | $19 | +21.6% | |
LHDX | Neutral | 04.02.2021 | $17 | -29.4% | |
VOR | Bullish | 04.02.2021 | $18 | +85.4% |